Staar Surgical issues letter to stockholders regarding Alcon merger

In conjunction with the definitive proxy filing, Staar (STAA) is mailing the following letter to Staar stockholders: “On August 5, 2025, we announced that STAAR Surgical Company entered into a definitive merger agreement to be acquired by Alcon (ALC) for $28.00 per share in cash. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. to ask for your vote to adopt the merger agreement. The STAAR Board of Directors unanimously determined that the proposed merger with Alcon is in the best interests of STAAR and its stockholders and strongly recommends that you vote “FOR” the merger proposal, as described in the accompanying proxy statement… We believe the value provided by the Alcon merger exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR’s lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves. Our business is heavily exposed to China, which faces significant economic uncertainty and where sales trends have been declining despite actions taken by the Company…”